Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Makers Laboratories Limited

NSE: MAKERSLPharmaceuticals

Share price

₹179.50

+0.16% close of 8 Oct 2026

Market cap ₹108 CrP/E 26.9

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 5 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

59

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹108 Cr

P/E ratio

26.9

P/B ratio

1.4

ROCE

9.3%

ROE

2.8%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹220.8652-week low ₹152.59

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 17.6% over the past year, and 5.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 10.1% to 12.3% over the last four years.

Whether it grew faster than its sector

It grew 5.3% a year against a sector median of 13.1% — 7.7 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.8 times its growth rate, on earnings growth of 35%.

Profit growthPrice per ₹1 profitPer 1% growth
Makers Laboratories Limited — this one35%/yr26.9×₹0.77
Viyash Scientific Limited73%/yr46.2×₹0.63
Strides Pharma Science Limited71%/yr17.4×₹0.25
Blue Jet Healthcare Limited15%/yr38.8×₹2.6
Procter & Gamble Health Limited19%/yr24.5×₹1.3
Sanofi Consumer Healthcare India Limited—31.1×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 90 of 130 on returns, 100 of 127 on growth, 95 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 9.3% on capital, ahead of 31% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹20 crore of cash from the business, spent ₹16 crore on plant and equipment, and returned ₹4 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 6 years, about 80 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 61 days for its cash to waiting 106 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 8 checks clear · 75%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 7 Aug 2026 · Consolidated · Unaudited

Revenue

₹43 Cr

Revenue vs last year

+22.2%

Revenue vs last quarter

+19.6%

Net profit

₹5 Cr

Profit vs last year

+256.3%

Profit vs last quarter

+29.1%

Net margin

10.7%

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹108 Cr
Prev close
₹179.50
52w High
₹236
52w Low
₹150
Enterprise value
₹114 Cr
Beta
—
Price CAGR 1y
29.0%
Price CAGR 3y
18.0%
Price CAGR 5y
-2.0%
Price CAGR 10y
11.0%

Ratios

Return on assets
4.8%
PEG ratio
0.9
P/E ratio
26.9
P/B ratio
1.4
EV / EBITDA
7.7
Industry P/E
38.0
ROCE
9.3%
ROCE 5y average
5.4%
ROE
2.8%
Debt / Equity
0.1
Interest coverage
12.0
Dividend yield
0.0%
ROE 3y average
-2.0%
ROE last year
3.0%

Annual P&L

Annual revenue
₹141 Cr
Annual profit
₹8 Cr
Operating margin
11.0%
Net profit margin
5.7%
EBITDA margin
10.6%
Sales growth 3y
11.8%
Sales growth 5y
15.4%
Profit growth 3y
35.0%
Profit growth 5y
49.0%
EPS
₹4.0
Sales growth TTM
18.0%
Profit growth TTM
-61.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹43 Cr
Profit latest quarter
₹5 Cr
YoY quarterly sales growth
22.2%
YoY quarterly profit growth
255.8%
OPM latest quarter
16.3%

Balance Sheet

Book Value
₹122
Face Value
₹10.0
Total debt
₹9 Cr
Total cash
₹1 Cr
Borrowings
₹9 Cr
Reserves / Equity
11.2

Cash Flow

Operating cash flow
₹14 Cr
Free cash flow
₹11 Cr
FCF yield
9.3%
Net cash flow
₹0 Cr

Shareholding

Promoter holding
61.3%
FII holding
—
DII holding
0.4%
Public holding
38.3%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.9033.94,27,5380.892,901.26.015,299.910.520.5
Divi's Lab.9,158.3081.62,43,1240.32902.065.53,080.027.822.0
Torrent Pharma.4,744.9080.91,80,4810.80566.05.84,921.054.915.2
Zydus Lifesci.1,141.0023.41,13,8150.09990.2-35.18,017.022.021.1
Cipla1,332.8530.11,07,6770.98785.6-39.27,119.32.315.5
Laurus Labs1,961.2096.91,05,9660.10362.1125.52,026.329.117.8
Mankind Pharma2,480.9048.11,02,4720.04574.129.64,030.612.913.5
Makers Labs.178.2030.81050.004.6240.942.822.29.3
Median413.5034.32,1540.0613.229.6160.318.614.9

Competes with: Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales25252728303028343534363643
Expenses25252627282726313232323036
Material Cost15
Change in Inventories-0.20
Purchases of Stock-in-Trade5.47
Employee Cost4.08
Other Expenses11
Operating Profit-0.140.200.200.861.812.191.313.093.012.284.165.286.96
OPM %-0.560.800.753.096.127.414.739.128.606.67121516
Other Income0.250.410.370.43-0.51110.870.100.270.360.330.760.61
Exceptional items (within Other Income)0
Interest0.410.490.530.520.490.430.190.180.180.220.200.170.15
Depreciation1.111.131.161.151.281.291.310.901.121.131.141.131.13
Profit before tax-1.41-1.01-1.12-0.38-0.47110.682.111.981.293.154.746.29
Tax %1811-4.46153491260253543282527
Net Profit-1.66-1.13-1.06-0.97-0.709.760.271.581.290.742.273.564.59
EPS in Rs-3.56-2.27-2.61-2.19-1.6615-0.51-0.080.75-0.201.591.852.54

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales69127101104121141148
Expenses6010898103112126130
Operating Profit8193191519
OPM %12153.301.1071113
Other Income13221122
Interest2222111
Depreciation5445555
Profit before tax316-1-4131115
Tax %5025161231930
Net Profit112-2-511811
EPS in Rs-0.568.44-8.05-11133.985.78
Dividend Payout %000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
15%
3 years
12%
TTM
18%

Compounded profit growth

10 years
—
5 years
49%
3 years
35%
TTM
-61%

Stock price CAGR

10 years
11%
5 years
-2%
3 years
18%
1 year
29%

Return on equity

10 years
—
5 years
-1%
3 years
-2%
Last year
3%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital556666
Reserves495563576567
Borrowings2123172289
Other Liabilities626266767085
Total Liabilities136144152161148167
Fixed Assets716885877471
CWIP090014
Investments2003012
Other Assets636667717381
Total Assets136144152161148167

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity018-91-414
Cash from Investing Activity0-221-720-15
Cash from Financing Activity0066-160
Net Cash Flow0-3-2-0-0-0
Free Cash Flow09-21-61111

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days883972708552
Inventory Days344166281227230250
Days Payable182389111279110
Cash Conversion Cycle250167262185236192
Working Capital Days1126111397140106
ROCE %151-249

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters616161616161616161616161
DIIs000000.390.390.390.390.390.390.39
Public393939393938383838383838
No. of Shareholders4,2834,1794,1764,0904,0084,0314,1354,0734,0263,9263,8013,745

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +17.6% (₹152.59 → ₹179.50)Brick size ₹11.58 (fixed)Bricks 7
₹150₹200₹225₹18019 Aug24 Aug
Price moved up one brickPrice moved down one brickLast close ₹179.50 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

News

News and filings about Makers Laboratories Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE987A01010

News impact

Big market events that reach Makers Laboratories Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

No dividends, splits or big trades on record.

Documents

Annual reports, results presentations and earnings calls, straight from the source.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.